Lupin is currently trading at Rs. 770.10, up by 6.10 points or 0.80% from its previous closing of Rs. 764.00 on the BSE.
The scrip opened at Rs. 764.00 and has touched a high and low of Rs. 780.00 and Rs. 761.65 respectively. So far 42150 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 979.90 on 14-Sep-2018 and a 52 week low of Rs. 697.30 on 19-Jun-2019.
Last one week high and low of the scrip stood at Rs. 780.00 and Rs. 753.70 respectively. The current market cap of the company is Rs. 34941.00 crore.
The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.66% and 14.38% respectively.
Lupin has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. The company is the first generic company to receive an approval for generic Inderal-LA Capsules for the Canadian market and the product has been approved and will be manufactured from Lupin’s Pithampur Unit-2 Facility.
Lupin’s Propranolol Hydrochloride ER Capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of Inderal-LA Capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.
Propranolol Hydrochloride ER Capsules (Canadian Reference Product: Inderal-LA Capsules) had an annual sales of approximately CAD 8.6 million (MAT December 2018 IQVIA).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.